Celldex Therapeutics, Inc. — Director's Dealing 2024

Feb 15, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2024-02-13

Reporting Person: Jimenez Freddy A. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-02-13	Common Stock	M	4166	$9.0165	Acquired	5924	Direct
2024-02-13	Common Stock	M	20000	$2.78	Acquired	25924	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-02-13	Incentive Stock Option (Right to Buy)	$9.0165	M	4166	Disposed	2028-06-13	Common Stock (4166)	Direct
2024-02-13	Incentive Stock Option (Right to Buy)	$2.78	M	20000	Disposed	2029-06-19	Common Stock (20000)	Direct

Footnotes

F1: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 62,500 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

F2: Includes 1,328 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.

F3: As of June 13, 2022, the option is fully vested.

F4: As of June 19, 2023, the option is fully vested.